Time filter

Source Type

Patent
Idcgs Clinica De Diagnosticos Medicos, University of Sao Paulo and Biocrates Life Sciences | Date: 2015-10-07

The present invention relates to a metabolic biomarker set for assessing HIV comprising at least one acylcarnitine (AC) and at least one sphingomyelin (SM). Moreover, the present invention relates to a method for assessing HIV in a mammalian subject which comprises obtaining a biological sample, preferably blood, from the subject and measuring in the biological sample the amount of at least one acylcarnitine (AC) and at least one sphingomyelin (SM), as well as to a kit adapted to carry out the method. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess HIV. In particular, it becomes possible to screen for and diagnose HIV in a patient with high accuracy and predict early in advance the patients therapeutic response to antiretroviral therapy.


Grant
Agency: European Commission | Branch: FP7 | Program: MC-IAPP | Phase: FP7-PEOPLE-2011-IAPP | Award Amount: 2.24M | Year: 2012

NATPROTEC aims to discover and carry to the stage of development innovative products in the area of cosmeceuticals originating from European natural resources using emerging and environmentally friendly technologies. These objectives will be implemented through an extended and balanced scheme of researchers exchanges and recruitments, in both directions and via a mutual scientific project developed on the needs and interests of both Industry and Academia sectors. More specifically, NATPROTEC scientific concept involves the discovery of novel natural products (NPs) originating from the Mediterranean and Alpine biodiversity. Already existing chemical libraries will be exploited incorporating modern high throughput platforms (in silico & in vitro) for the rational and targeted selection of the optimum natural sources. Advanced analytical approaches and techniques will be applied for the efficient, accelerated and advantageous isolation and identification procedures of natural constituents as well as the quality assessment of the lead products. A broad spectrum of bioassays and novel analytical approaches will be incorporated for the evaluation of skin-protecting, anti-ageing and anti-hyperpigmenting activity of all derived products. Attention will be given to the selection of the optimum source of the biomaterial to ensure sustainability and into the development, optimisation and application of novel, green technologies for the production of the final lead products. Within this frame, core scientific knowledge and lead compounds for further development are expected to be produced creating valuable synergies. Expertise will be transferred by means of the seconded researchers training in environments with different dynamics and orientation where other skills are required. NATPROTEC aspires to comprise a successful model of an efficient, long-lasting collaboration between Industry and Academia for sustainable exploitation of existing know-how and produced knowledge.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: KBBE.2011.2.2-02 | Award Amount: 7.84M | Year: 2012

NutriTech will build on the foundations of traditional human nutrition research using cutting-edge analytical technologies and methods to comprehensively evaluate the diet-health relationship and critically assess their usefulness for the future of nutrition research and human well-being. Technologies include genomics, transcriptomics, proteomics, metabolomics, laser scanning cytometry, NMR based lipoprotein profiling and advanced imaging by MRI/MRS. All methods will be applied in an integrated manner to quantify the effect of diet on phenotypic flexibility, based on metabolic flexibility (the capacity for the organism to adapt fuel oxidation to fuel availability). However, NutriTech will move beyond the state-of-the-art by applying these integrated methods to assess the underlying and related cell biological and genetic mechanisms and multiple physiological processes of adaptation when homeostasis is challenged. Methods will in the first instance be evaluated within a human intervention study, and the resulting optimal methods will be validated in a number of existing cohorts against established endpoints. NutriTech will disseminate the harmonised and integrated technologies on a global scale by a large academic network including 6 non-EU partners and by providing an integrated and standardised data storage and evaluation platform. The impact of NutriTech will be multifold and exploitation is crucial as major breakthroughs from our technology and research are expected. This will be achieved by collaboration with a consortium of 8 major food industries and by exploitation of specific technologies by our 6 SME partners. Overall, NutriTech will lay the foundations for successful integration of emerging technologies intro nutrition research.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.2.2.2-2 | Award Amount: 3.88M | Year: 2012

Healthy brain ageing is a major determinant of quality life-long health, allowing integration into society at all ages. Human epidemiological and animal studies indicate that in addition to life style and genetic factors, environmental influences in prenatal life have a major impact on brain ageing and age-associated brain disorders. We hypothesize that: (1) prenatal stress programs early brain ageing; (2) this predisposes to age-associated brain diseases including cognitive decline and stroke; (3) epigenetic changes affecting glucocorticoid receptor (GR) sensitivity, altered autonomic nervous system (ANS) reactivity and cerebrovascular tone are important mediators of these processes, (4) these changes represent targets for diagnosis and therapeutic interventions. Our consortium has unique access to well-defined human and non-human primate cohorts (age range 25-115 y equivalents) that have been exposed to different types of prenatal stress. For experimental analysis of mechanisms of prenatal programming, we apply innovative techniques to characterize brain ageing, namely MRI based volumetry, non-linear analysis of EEG and ANS, advanced molecular techniques including epigenetics and metabolomics and neuropsychological and behavioral tests. Human subjects, non-human primates and rodents (including transgenic models) exposed to maternal stress, glucocorticoids or undernutrition are examined in order to: (1) determine structural (MRI based volumetry) and functional (metabolomics, brain function, cerebrovascular tone) indicators of brain age, (2) relate them to susceptibility to stroke and cognitive decline, (3) determine to what extent GR resistance, stress sensitivity, and cerebrovascular contractility mediate premature brain ageing and disease susceptibility; and, (4) dissect mechanisms and pharmacological interventions relevant for aged subjects. Data from the study allow to identify subjects at risk for premature brain ageing and to initiate interventional therapy.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.2.4.2-2 | Award Amount: 7.85M | Year: 2011

Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond European risk scores, their comparative impact among different European regions and their role in the drive towards personalised medicine remains uncertain. Based on harmonised and standardised European population cohorts we have built significant research collaboration, expertise and infrastructure in the EU. We will apply highly innovative SME-driven technologies and perform large-scale biomarker determination to assess the predictive value of existing and emerging biomarkers. Selection of emerging biomarkers will be based on integrated cutting-edge quantitative proteomic, transcriptomic, metabolomic, and miRNomic datasets established by private and public consortium members that will be disclosed to this consortium. Existing biomarkers will be selected based on non-redundancy and their association with cardiovascular risk and phenotypes. After SME-guided development of innovative assay systems biomarkers will be tested and validated in a stepwise fashion among European populations in primary and secondary prevention. In addition to their impact on risk prediction, their association with lifestyle determinants and cardiovascular phenotypes assessed by ultrasound and MRI technique will be evaluated. We will establish a BiomarCaRE panel which leads to improved disease prediction among different European populations. International collaborations with world-class clinical trial investigators will add data on the interaction of the BiomarCaRE panel with risk-lowering medication and lifestyle changes. The outcome of SME-driven technology development and clinical validation will undergo a medical technology assessment. The determination of cost-effectiveness will guide further clinical evaluation. These studies will reveal new methods of improved cardiovascular risk estimation and will open the path towards personalised medicine.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.4.2-1 | Award Amount: 8.33M | Year: 2014

Asymptomatic vascular damage accumulates for years before patients are identified and subjected to therapeutic measures. The limited knowledge on early vascular disease pathophysiology is reflected in the lack of therapeutic options. SysVasc aims to overcome this limitation by mounting a comprehensive systems medicine approach to elucidate pathological mechanisms, which will yield molecular targets for therapeutic intervention. The consortium is based on established multidisciplinary European research networks, including specialists in pre-clinical and clinical research, omics technologies, and systems biology from research intensive SMEs and academia; partners synergistically provide access to an extensive number of selected population-based cohorts and associated datasets, cutting edge modeling and simulation methods, and established cardiovascular disease (CVD) animal models and patient cohorts. The coordinated application of these tools and know-how will identify pathophysiological mechanisms and key molecules responsible for onset and progression of CVD and validate their potential to serve as molecular targets for therapeutic intervention. To this end, the consortium will also use unique resources to evaluate molecular homology between the available model systems and human disease, which will yield reliable essential preclinical research tools to explore proof of concepts for therapeutic intervention studies and ultimately translate relevant results into novel therapeutic approaches. Collectively, SysVasc will identify and validate novel biology-driven key molecular targets for CVD treatment. Major scientific, societal and economic impact is expected including, but not limited to, providing a valuable resource to further CVD research, and enhance competitiveness of participating SMEs and European health industry in general by translating knowledge into innovative services in therapeutic target and drug research.


Patent
Biocrates Life Sciences | Date: 2015-08-12

The present invention relates to a biomarker and a method for determining an oxidative stress level in a biological sample, which employs co-factor-dependent oxidative stress parameters, as well as a kit adapted for carrying out such a method. In one aspect the co-factor is tetrahydrobiopterin.


Patent
Biocrates Life Sciences | Date: 2016-08-29

The present invention relates to a metabolic biomarker set for assessing kidney disease comprising at least two amino acids, at least two acylcarnitines and at least two biogenic amines. Moreover, the present invention relates to a method for assessing kidney disease in a mammalian subject which comprises obtaining a biological sample, preferably blood and/or urine, from the subject and measuring in the biological sample the amount of at least two amino acids, of at least two acylcarnitines and of at least two biogenic amines, as well as to a kit adapted to carry out the method. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess kidney disease.


Patent
Biocrates Life Sciences | Date: 2015-11-11

The present invention relates to a method and kit for in vitro diagnosing a complex disease such as cancer, in particular, colon cancer, kidney cancer, prostate cancer; transient ischemic attack (TIA), ischemia, in particular stroke, hypoxia, hypoxic-ischemic encephalopathy, perinatal brain damage, hypoxic- ischemic encephalopathy of neotatals asphyxia; demyelinating disease, in particular, white-matter disease, periventricular leukoencephalopathy, multiple sclerosis, Alzheimer and Parkinsons disease; in a biological sample. For the diagnosis, use is made of measuring at least two different species of biomolecules and classifying the results by means of suitable classifier algorithms and other statistical procedures. With the present invention, a significant improvement of the reliability of, e.g. expression profiles alone, are achieved. In other words, in a defined collective, an up to 100% accurate positive diagnosis could be achieved, which renders the method of the present invention superior over the prior art.


Grant
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 2.86M | Year: 2017

The consolidation of the knowledge that cancer is not only a genetic, but also a metabolic disease, has led scientists to investigate the intricate metabolic plasticity that transformed cells must undergo to survive the adverse tumor microenvironment conditions, and the contribution of oncogenes and tumor suppressors in shaping metabolism. In this scenario, genetic, biochemical and clinical evidences place mitochondria as key actors in cancer metabolic restructuring, not only because these organelles have a crucial role in the energy and biosynthetic intermediates production but also because occurrence of mutations in metabolic enzymes encoded by both nuclear and mitochondrial DNA has been associated to different types of cancer. TRANSMIT aims to dissect the metabolic remodeling in human cancers, placing the focus on the role of mitochondria and bridging basic research to the improvement/development of therapeutic strategies. Further, TRANSMIT fosters the communication of this emerging field to the patients and their families. To these aims, TRANSMIT will create a network of seven different countries, among which world-leading basic science and clinical centers of excellence, several industrial partners with up-to-date omics technologies, as well as non-profit foundations and associations who care for cancer patients. By creating the critical mass of scientific excellence, TRANSMIT will allow to transfer the current knowledge into the wide field of cancer research, translating scientific and technical advances into the education and training of eleven Early Stage Researchers. TRANSMIT will implement training-through-research dedicated to unravel the metabolic features of cancer, as well as to provide a full portfolio of complementary skills through the creation of a network of basic, translational and industrial laboratories, devoted to a multidisciplinary/multisectorial education of young scientists.

Loading Biocrates Life Sciences collaborators
Loading Biocrates Life Sciences collaborators